Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 4, 2010, Pages 745-753

  Yagi, Yasumichi ^a   Fushida, Sachio ^a   Harada, Shinichi ^a   Tsukada, Tomoya ^a   Kinoshita, Jun ^a   Oyama, Katsunobu ^a   Fujita, Hideto ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Kayahara, Masato ^a   Kinuya, Seigo ^a   Yashiro, Masakazu ^b   Hirakawa, Kousei ^b   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Biodistribution; Iodine 125 label; Molecular targeted therapy; Peritoneal metastasis

Indexed keywords

BEVACIZUMAB; IODINE 125; PACLITAXEL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COLORING AGENT; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CONTROLLED STUDY; CYTOSTASIS; DISEASE MODEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG UPTAKE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; PATHOLOGY; PERITONEUM TUMOR; STOMACH TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION; TUMOR CELL LINE; WESTERN BLOTTING; CANCER INHIBITION; CYTOKINE RELEASE; LOCAL THERAPY; SUBCUTANEOUS TISSUE TUMOR; SYSTEMIC THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; COLORING AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 78149327921     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1219-y     Document Type: Article

References (45)

1. Holm-Nielsen P (1953) Pathogenesis of ascites in peritoneal carcinomatosis. Acta Palhol Microbiol Scand 33:10-21
2. Feldman GB, Knapp RC, Order SE, Hellman S (1972) The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32:1663-1666
3. Feldman GB, Knapp RC (1974) Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol 119:991-994
4. Brown HR (1976) Kinetics of angiogenesis in small vessels related to mouse parietal peritoneum. Anal Ree 184:364
5. Heuser LS, Taylor SH, Folkman J (1984) Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis. J Surg Res 36:244-250
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985
7. Garrison RN, Kaelin LD, Heuser LS, Galloway RH (1986) Malignant ascites clinical and experimental observations. Ann Surg 203:644-649
8. Garrison RN, Galloway RH, Heuser LS (1987) Mechanisms of malignant ascites production. J Surg Res 42:126-132
9. Brown LF, Detmar M, Claffey K et al (1997) Vascular permeability factor/vascular endothelial growth factors: a multifunctional angiogenic cytokine. EXS 79:233-269
10. Ferrera N (1996) Vascular endothelial growth factor. Eur J Cancer 32 A: 2413-2422
11. Pepper MS, Wasi S, Ferrera N, Orci L, Montesano R (1994) In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. Exp Cell Res 210:298-305 (Pubitemid 24168528)
12. Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2:167-182
13. Yeo KT, Wang HH, Nagy JA et al (1993) Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918
14. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256
15. Nagy JA, Masse EM, Herzberg KT et al (1995) Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55:360-368
16. Kakeji Y, Koga T, Sumiyoshi Y et al (2002) Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res 16:125-129
17. Aoyagi K, Kouhuji K, Yano S et al (2005) VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 8:155-163
18. Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54:707-710
19. Kraft A, Weindel K, Ochs A et al (1999) Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85:178-187
20. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917-1924
21. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11:6966-6971
22. Byrne AT, Ross L, Holash J et al (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721-5728
23. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087-1092
24. Shah MA, Ramanathan RK, Ilson DH et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206
25. Pinto C, Di Fabio F, Siena S et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510-517
26. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955
27. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007
28. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
29. Ninomiya S, Inomata M, Tajima M et al (2009) Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 154:196-202
30. Mabuchi S, Terai Y, Morishige K et al (2008) Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 14:7781-7789
31. Liang WC, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951-961
32. Lin YS, Nguyen C, Mendoza JL et al (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378
33. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14:43-54
34. Nakamura K, Kubo A (1997) Biodistribution of iodine-125 labeled monoclonal antibody/interleukin-2 immunoconjugate in athymic mice bearing human tumor xenografts. Cancer 80:2650-2655
35. Kinuya S, Yokoyama K, Kawashima A et al (2000) Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. J Nucl Med. 41:1244-1249
36. Kinuya S, Yokoyama K, Izumo M et al (2005) Locoreginal radioimmunotherapy with 186Re-labeled monoclonal antibody in treating small peritoneal carcinomatosis of colon cancer in mice in comparison with 131I-counterpart. Cancer Lett 219:41-48
37. Kinuya S, Li XF, Yokoyama K et al (2003) Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy. Cancer Sci 94:650-654
38. Kinuya S, Yokoyama K, Fukuoka M et al (2007) Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model. Nucl Med Commun 28:129-133
39. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T (2002) Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 61:570-578
40. Sako A, Kitayama J, Yamaguchi H et al (2003) Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 115:113-120
41. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
42. Belotti D, Vergani V, Drudis T et al (1996) The microtubule affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849
43. Browder T, Butterfield CE, Kräling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer 60:1878-1886
44. Ma J, Waxman DJ (2008) Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7:3670-3784
45. Ishigami H, Kitayama J, Otani K et al (2009) Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76:311-314